Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 20, Issue 7, Pages 941-956Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.2010.484804
Keywords
cardiovascular diseases; diabetes; EPHX2; hypertension; metabolic syndrome; sEH; sEH inhibitors; soluble epoxide hydrolase
Categories
Ask authors/readers for more resources
Importance of the field: Soluble epoxide hydrolase (sEH) inhibitors have been shown to effectively increase the levels of epoxyeicosatrienoic acids and reduce the levels of dihydroxyeicosatrienoic acids, which may be translated to therapeutic potentials for multiple disease indications. It has been claimed that sEH inhibitors can be used to treat hypertension, diabetes, stroke, dyslipidemia, pain, immunological disorders, eye diseases, neurological diseases and other indications. Areas covered in this review: A comprehensive synopsis of patent literature on sEH inhibitors is provided. What the reader will gain: A total of more than 100 patent publications describing multiple classes of sEH inhibitors are analyzed. These include amides, ureas, thioamides, thioureas, carbamates, acyl hydrazones, chalcone oxdies, etc. In addition to selected in vitro and in vivo data of representative sEH inhibitors, a wide range of proposed applications of sEH inhibitors are also summarized. Take home message: Several sEH inhibitors with potent in vitro and in vivo target inhibition appear promising, including one Phase II clinical candidate. The clinical evaluation will be critical to assess the proclaimed therapeutic utility of sEH inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available